https://lnkd.in/euvikRzZ Gilde Healthcare is excited that its portfolio company Purespring Therapeutics is one step closer to demonstrating that PS-002 can target the underlying cause of patients suffering from primary IgA nephropathy (IgAN). IgAN is a chronic autoimmune kidney disease that primarily affects young adults. PS-002 is the first to modulate complement activation in the kidney via precision targeting of podocytes. The approval enables to start clinical trials in patients with primary IgA nephropathy. #LifeSciences #Biotech #GildeHealthCare #nephrology #phase1 #IND Arthur Franken Sonia Hallen Marion Pouillard
